Moreover, compared with monotherapy, the combined use of anti-CTLA-4 and anti-PD-1 has demonstrated prolonged progression-free survival and significant tumor regression in clinical trials of cancer patients (176, 177). This evidence concerns the gene PDCD1 and neoplasm.